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Abstract
The mouse spot test, an in vivo mutation assay, has been used to assess a number of chemicals. It
is at present the only in vivo mammalian test system capable of detecting somatic gene mutations
according to OECD guidelines (OECD guideline 484). It is however rather insensitive, animal
consuming and expensive type of test. More recently several assays using transgenic animals have
been developed. From data in the literature, the present study compares the results of in vivo
testing of over twenty chemicals using the mouse spot test and compares them with results from
the two transgenic mouse models with the best data base available, the lacI model (commercially
available as the Big Blue® mouse), and the lacZ model (commercially available as the Muta™
Mouse). There was agreement in the results from the majority of substances. No differences were
found in the predictability of the transgenic animal assays and the mouse spot test for
carcinogenicity. However, from the limited data available, it seems that the transgenic mouse assay
has several advantages over the mouse spot test and may be a suitable test system replacing the
mouse spot test for detection of gene but not chromosome mutations in vivo.
Background
This is the second presentation from a project for the
International Programme on Chemical Safety (IPCS) eval-
uating the possible use of transgenic animal mutagenicity
assays in toxicity testing and mechanistic research. Part I,
preceeding this article, discussed comparison of effects of
chemicals using certain transgenic assays with results
using the bone marrow micronucleus test.
The assessment of the potential genotoxicity of chemicals
in vivo is important for both the verification and confirma-
tion of intrinsic mutagenicity and for establishing the
mode of action of chemical carcinogens. Although the
present trend is to reduce animal testing, in vitro data must
be confirmed by testing in in vivo conditions which take
into account whole animal processes like absorption, tis-
sue distribution, metabolism and excretion of the chemi-
cal and its metabolites, and overall toxicity [1]. In the mid
1980s, the mouse spot test [2] was suggested as a comple-
mentary in vivo test to the bacterial mutagenicity assay for
detection of mutagenic substances and as a confirmatory
test for the identification of carcinogens [3]. The mouse
spot test has been used to assess a number of chemicals
(see e.g. Additional file 1, see separate file). It is at present
the only in vivo mammalian test system capable of detect-
ing somatic gene mutations according to OECD guide-
lines (OECD guideline 484 [4]). However to achieve an
acceptable sensitivity, a large number of animals are
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necessary and it is therefore an expensive type of test and
seldom used. More recently assays using transgenic ani-
mals have been developed for testing in vivo gene muta-
genicity. The two transgenic mouse models with the best
data base available are the lacI model (commercially avail-
able as the Big Blue® mouse), and the lacZ model (com-
mercially available as the Muta™ Mouse). The present
study compares the results of in vivo testing of a number
of chemicals using the mouse spot test and compares it
with results from these two transgenic mouse models.
Descriptions of test systems
Mouse spot test
In the spot test, mouse embryos which are heterozygous
for different recessive coat colour genes, are treated in utero
at gestation day 9–11 with the test substance. The exposed
embryo at gestation day 10 contains about 150–200
melanoblasts and each melanoblast has 4 coat colour
genes under study [2,5]. The in utero exposure may result
in an alteration or loss of a specific wild-type allele in a
pigment precursor cell resulting in a colour spot in the
coat of the adult animal. The frequency of spots is com-
pared with the frequency in sham-exposed controls [2,4].
In the mouse spot test there are 4 possible mechanisms by
which the recessive coat-colour alleles can be expressed:
1) gene mutation in the wild-type allele, 2) deficiency
(large or small) of a chromosomal segment involving the
wild-type allele, 3) nondisjunctional (or other) loss of the
chromosome carrying the wild-type allele and 4) somatic
recombination (marker gene then homozygous) [5].
Gene mutagenic but also clastogenic effects are detected
by this test system.
Transgenic mouse models
The transgenic mutation test systems the lacI model (Big
Blue® mouse), and the lacZ model (Muta™ Mouse) are
described in detail in the preceding article: Mutagenicity
testing with transgenic mice. Part I: Comparison with the
mouse bone marrow micronucleus test
Methods
Data presented in this documentation are the results of an
extensive literature research. Concerning data on trans-
genic mouse assays only primary literature was used. Data
on the mouse spot test were extracted from reliable
reviews on this item or from primary literature. For all
other data informations from secondary literature or data
banks were used.
Results and Discussion
Comparison of the mouse spot test with transgenic mouse 
model systems
In the literature search chemicals have been identified that
had been tested using the spot test and the Muta™ mouse
assay (n = 20) or the Big Blue® mouse assay (n = 9) or both
transgenic mutation assays (n = 8). The results (including
references) are given in Additional file 1.
The results on 15 out of 20 substances (2-acetylaminoflu-
orene, acrylamide, benzo[a]pyrene, 1,3-butadiene, cyclo-
phosphamide, ethylmethanesulfonate, N-ethyl-N-
nitrosourea,  N-methyl-N'-nitro-N-nitrosoguanidine,  N-
methyl-N-nitrosourea, 4-nitroquino-line-1-oxide, N-
nitrosodiethylamine,  N-nitrosodimethylamine, procar-
bazine, 4-acetylaminofluorene and N-propyl-N-nitrosou-
rea) showed agreement between the Muta™ mouse and
the mouse spot test. No agreement was seen with 5 out of
20 substances (4-acetylaminofluorene, 2-amino-3-meth-
ylimidazo(4,5-f)quinoline (IQ), hydrazine, mitomycin C,
trichloroethylene).
The positive results obtained with the Big Blue® mouse
assay agreed with results in the mouse spot test for 7 out
of 9 substances (2-acetylaminofluorene, benzo[a]pyrene,
1,3-butadiene, cyclophosphamide, N-ethyl-N-nitrosou-
rea,  N-methyl-N-nitrosourea,  N-nitrosodimethylamine);
one (di-(2-ethylhexyl)phthalate) was negative in both test
systems and only one (methyl methanesulfonate) showed
no agreement between the two test systems.
With two exceptions, 4-acetylaminofluorene and N-pro-
pyl-N-nitrosourea (discussed later), all of the tested sub-
stances showed also clearly positive results in in vitro gene
mutation assays (exception of 1,3-butadiene, negative
results) and in the majority of in vivo studies on this end-
point. Further they induced carcinogenic effects in long-
term studies on mice.
Although no data on carcinogenicity on mice is available
on N-propyl-N-nitrosourea, this substance might also be
included in the category mentioned above, since carcino-
genic effects were reported in rats [113] and in vitro gene
mutation assays revealed clearly positive results.
The following substances did not show agreement
between results in the mouse spot test and transgenic
mouse assays or negative results were reported in both test
systems (see Additional file 1). These are therefore dis-
cussed in more detail here; for references see Additional
file 1.
4-Acetylaminofluorene
This substance showed mutagenic activity in the Muta™
mouse assay [19] but negative results in the mouse spot
test [12,13]. No data on carcinogenicity are available on 4-
acetylaminofluorene. However, data on two in vitro test
systems indicated gene mutagenic activity supporting
results in the transgenic assay [15-18].Journal of Carcinogenesis 2005, 4:4 http://www.carcinogenesis.com/content/4/1/4
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2-Amino-3-methylimidazo(4,5-f)quinol (IQ)
IQ is mutagenic in the Muta™ mouse assay [28] but nega-
tive results were obtained in the mouse spot test [29]. This
negative result in the mouse spot test is in contrast to all
other in vivo gene mutation assays on rodents and insects
which revealed positive results [27]. Furthermore, gene
mutagenic activity was detected in in vitro test systems and
carcinogenic effects were observed in long-term studies on
mice [27]. The results in the Muta™ mouse assay are in
accordance with these data.
Di-(2-ethylhexyl)phthalate
Negative results in the mouse spot test [51] are in agree-
ment with the negative Big Blue® assay [11]. Furthermore
no gene mutagenic or questionable activity was reported
in in vitro tests and in tests on Drosophila. Carcinogenic
effects were obtained in studies on mice but nongenotoxic
mechanisms are presumed.
Hydrazine
This substance induced mutagenic effects in the mouse
spot test [72] but negative results were observed in the
Muta™ mouse assay [71]. Other in vivo as well as in vitro
test systems revealed gene mutagenic effects [70].
Increased tumor incidences were observed in carcino-
genicity studies on mice. Overall, the mouse spot test but
not the Muta™ mouse assay reflects data on genotoxicity
and carcinogenicity. However, a single exposure was used
in the Muta™ mouse assay [71]. Studies on other in vivo
genotoxicity endpoints have shown generally negative
results after single exposure but genotoxic activity after
repeated application, for example the mouse bone mar-
row micronucleus assay was positive [20]. It is possible
that positive results may be found using another experi-
mental design in the Muta™ mouse assay e.g. repeated
exposure.
Methyl methanesulfonate
Only weak mutagenic effects were observed in the Muta™
mouse [19,57,75-77] and negative results in the Big Blue®
mouse [63-65,78]. In the mouse spot test this carcino-
genic substance is mutagenic [3] as well as in other gene
mutation assays in vitro and  in vivo [73,74]. However,
there is evidence that the chromosome mutagenic activity
is detectable at much lower doses than the gene muta-
genic activity. Tinwell et al. [19] have shown in Muta™
mice a weak gene mutagenic effect in the liver but no
effect in the bone marrow. The same dose induced in
these animals a significant increase in bone marrow
micronuclei indicating clear clastogenic activity. However,
the transgenic mutation assay is less suitable for detection
of these effects [1].
Mitomycin C
No mutagenic activity was observed in the Muta™ mouse
assay after single application and ambiguous results after
repeated exposure [93] but positive results were obtained
with the mouse spot test [2,3] and other gene mutation
assays in vitro and in vivo with this carcinogenic substance
[90-92]. The reason for this discrepancy is similar to that
presumed for methyl methanesulfonate above. Clas-
togenicity in bone marrow but no gene mutagenic activity
in liver and bone marrow has been shown in the same
animals in the Muta™ mouse assay combined with a
micronucleus assay [93]. However, using another experi-
mental design for detection of gene mutations in the
Muta™ mouse assay (dose level up to the MTD, repeated
exposure) positive results might be obtained.
Table 1: Characteristics of the Muta™ mouse assay and the Big Blue® mouse assay for predicting mouse carcinogenicity in comparison 
with the mouse spot test
Term# Calculation* for the mouse spot test Calculation* for Muta™ and/or Big Blue® 
mouse combined **
Sensitivity 84% (16/18) 79% (15/18)
Specificity 0 (0/0) 0 (0/0)
Positive predictability 100% (16/16) 100% (15/15)
Negative predictability 0 (0/2) 0 (0/3)
Overall accuracy 84% (16/18) 79% (15/18)
# Sensitivity = % of carcinogens with a positive result in the specified test system (STS)
Specificity = % of noncarcinogens with a negative result in the STS
Positive predictivity = % of positive results in the STS that are carcinogens
Negative predictivity = % of negative results in the STS that are noncarcinogens
Overall accuracy = % of chemicals tested where STS results agree with the carcinogenicity results
*: carcinogens with genotoxic and nongenotoxic mechanisms were considered but not substances without data on carcinogenicity; only data on 
mice were used
**: judged as positive in transgenic assays if positive in one of the two test systems
For methylmethanesulfonate, the weak positive results were judged as positive.
Trichloroethylene was not included in the calculation (inconclusive results in the mouse spot test).Journal of Carcinogenesis 2005, 4:4 http://www.carcinogenesis.com/content/4/1/4
Page 4 of 8
(page number not for citation purposes)
Trichloroethylene
Also with this carcinogenic substance, no mutagenicity
was detected in the Muta™ mouse assay [117], the mouse
spot test was positive [3], but this result is possibly related
to contaminations with epoxides [116]. Further in vitro
and in vivo assays on gene mutation resulted in weak pos-
itive, questionable, or negative effects [116]. Results in
chromosome mutation assays are equivocal. However, a
further (simple) reason for this discrepancy between the
Muta™ mouse assay and the mouse spot test might be that
the MTD was not reached in the Muta™ mouse assay pre-
sented by Douglas et al. [117].
In general, from the studies on genotoxic carcinogens
given above, the results do not seem to give a preference
for either the spot test or transgenic mouse model system.
However, considering the mechanisms of action of spe-
cific substances there is some evidence, that the mouse
spot test detects gene mutations as well as chromosome
mutations whereas the transgenic mouse assays are
restricted to gene mutations. Evidence for this hypothesis
has been shown with the examples methyl methanesul-
fonate, mitomycin C, and trichloroethylene. In the mouse
spot test, there are four possible mechanisms by which the
recessive coat-colour alleles can be expressed (see intro-
duction) including gene and chromosome mutations.
Although the chromosome mutations have to survive sev-
eral mitoses to cause the expression of the recessive allele
[118], there is evidence that also predominantly clas-
togenic substances might result in a positive mouse spot
test. In contrast, the transgenic mutation assays detected
point mutations and maximal small deletions and inser-
tions [1].
Predictivity of the transgenic animal assays and the mouse 
spot test for carcinogenicity
The sensitivity, specificity and predictivity of carcinogenic-
ity for the transgenic mouse model (Muta™ mouse assay
and the Big Blue® mouse assay combined) and the mouse
spot test are documented in Table 1. Data on 18 sub-
stances (see Additional file 1) are available on carcino-
genicity in mice and mutagenic effects in transgenic mice
as well as mutagenic effects in the mouse spot test (trichlo-
roethylene not included because of inconclusive results in
the mouse spot test).
Although the data pool is not sufficient for a comprehen-
sive comparison, there is some indication, that no signifi-
cant differences were detectable between the two test
systems.
Advantages and disadvantages of both test systems
Sensitivity of the test system
In comparison to models using endogenous genes like the
target genes in the mouse spot test, the spontaneous
mutant frequency in transgenic animals is relatively high.
This might be due to the fact that bacterial DNA is the tar-
get gene (high methylation rate) and/or the transgene is
silent and no transcription related repair occurs as in
endogenous genes which are more efficiently repaired [1].
However, comparing the number of cells and genes at risk
at the time of exposure, the mouse spot test is numerical
inferior to the transgenic mouse mutation assays. In the
mouse spot test, the exposed embryo at gestation day 10
contains about 150–200 melanoblasts and each melano-
blast has 4 coat colour genes under study [2,5]. In the
transgenic Big Blue® mouse, for example, 30–40 copies of
the target gene (the constructed λLIZα shuttle vector) are
integrated on chromosome 4 of each cell of the animal
[1].
Other factors
To achieve an acceptable sensitivity, a large number of
animals are necessary in the mouse spot test. Many preg-
nant dams have to be in one treatment group to get a suf-
ficient number of surviving F1-animals, since the test
substance may induce maternal and developmental toxic-
ity. Fahrig [2] suggested that 30–40 pregnant mice are
needed per treatment group for evaluation of spots in the
progeny. At least 150 F1-mice are recommended for the
concurrent vehicle control [5] and at least two dose
groups are used (OECD guideline 484 [4]). Therefore, the
mouse spot test is an expensive type of in vivo test.
In contrast, in transgenic mutation assays ca. 20 animals
(3 dose groups and 1 concurrent vehicle control group in
laboratories which already established this test system)
are recommended per species and gender [119-121].
In the mouse spot test the discrimination between spots
of mutagenic and non-mutagenic origin may be problem-
atic [2].
A comparison of both test systems is presented in Table 2.
Conclusions
Although the mouse spot test is a standard genotoxicity
test system according to the OECD guidelines, this system
has seldom been used for detection of somatic mutations
in vivo in the last decades. This is partly due to considera-
tions of cost effectiveness and number of animals needed
for testing but also for toxicological considerations. The
usefulness of the mouse spot test in toxicology is limited
by restrictions in toxicokinetics, sensitivity, target cell/
organ, and molecular genetics. From the limited data
available, it seems that the transgenic mouse assay hasJournal of Carcinogenesis 2005, 4:4 http://www.carcinogenesis.com/content/4/1/4
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several advantages over the mouse spot test and may be a
suitable test system replacing the mouse spot test for
detection of gene but not chromosome mutations in vivo.
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